8-K: CytoSorbents Postpones Earnings Release Following Corporate Controller's Passing, Reaffirms Financial Expectations

CytoSorbents Corp. announces a delay in its earnings release due to the passing of its Vice President and Corporate Controller, while reaffirming preliminary financial expectations for Q4 and full-year 2024.

Summary

• CytoSorbents Corporation has postponed its earnings call, originally scheduled for March 6, 2025, to March 25, 2025, due to the passing of its Vice President and Corporate Controller.
• The company reaffirms its previously provided preliminary financial results for the quarter and full year ended December 31, 2024.
• Fourth quarter product revenue is expected to be in the range of $9.0 million to $9.2 million, representing 22% to 25% growth compared to $7.35 million in Q4 2023.
• Full-year product revenue is expected to be in the range of $35.4 million to $35.6 million, representing approximately 14% growth compared to $31.1 million for the full year 2023.
• The company anticipates a fourth quarter product gross margin of approximately 70%, compared to 61% in the prior quarter and 72% in the fourth quarter of 2023.
• Regulatory decisions on DrugSorb-ATR marketing applications are still expected in 2025 from both the U.S. FDA and Health Canada.
• The company's pro forma cash balance on December 31, 2024, after giving effect to the Rights Offering and the exercise of Series A Right Warrants, would have been approximately $17.0 million, including unrestricted cash of approximately $15.5 million.
• This reflects $7.3 million in net proceeds raised and net cash used in the fourth quarter of 2024 of approximately $2.5 million.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the reaffirmation of financial expectations is positive, the delay in the earnings release due to the passing of a key executive introduces a somber tone and potential uncertainty.

Positives

• The company reaffirms its previously provided preliminary financial results for the quarter and full year ended December 31, 2024.
• Fourth quarter product revenue is expected to be in the range of $9.0 million to $9.2 million, representing 22% to 25% growth compared to $7.35 million in Q4 2023.
• Full-year product revenue is expected to be in the range of $35.4 million to $35.6 million, representing approximately 14% growth compared to $31.1 million for the full year 2023.
• The company anticipates a fourth quarter product gross margin of approximately 70%.
• The company's marketing applications for DrugSorb-ATR continue to be in substantive and interactive review with the U.S. FDA and Health Canada, and the Company continues to expect regulatory decisions from both agencies in 2025.
• The pro forma cash balance on December 31, 2024, after giving effect to the Rights Offering and the exercise of Series A Right Warrants, would have been approximately $17.0 million, including unrestricted cash of approximately $15.5 million.

Negatives

• The earnings release and conference call have been postponed due to the unexpected passing of the company's Vice President and Corporate Controller.

Risks

• The estimated financial results, proforma cash balance and estimate of cash utilized in the fourth quarter remain preliminary and unaudited.
• The company's future performance is subject to risks discussed in their Annual Report on Form 10-K and other filings with the SEC.

Future Outlook

The company expects regulatory decisions on DrugSorb-ATR marketing applications in 2025 and will report Q4 and full-year 2024 financial results on March 25, 2025.

Management Comments

• Dr. Phillip Chan, CEO, expressed sadness over the loss of James E. Cason, Jr., the company's Vice President and Corporate Controller, highlighting his contributions to the company's growth and mission.
• Dr. Chan stated that the extension of time for the audit is a prudent decision to ensure thorough completion of the year-end audit.

Industry Context

CytoSorbents operates in the blood purification market, focusing on critical care and cardiac surgery. The company's technology aims to address life-threatening conditions by removing toxic substances from the blood. Regulatory approvals for DrugSorb-ATR would position the company to compete in the antithrombotic removal market.

Comparison to Industry Standards

• It's difficult to directly compare CytoSorbents to larger, diversified medical device companies like Medtronic or Baxter International, as they have a more focused product portfolio.
• However, their revenue growth and gross margin can be benchmarked against smaller, specialized companies in the blood purification or critical care space.
• For example, companies like Fresenius Medical Care or DaVita, which focus on dialysis and kidney care, may provide some context for revenue multiples and growth rates, although their business models are different.
• The success of DrugSorb-ATR will be crucial in determining CytoSorbents' competitive positioning in the antithrombotic market, where companies like Haemonetics also operate.

Stakeholder Impact

• Shareholders may experience a delay in receiving detailed financial information.
• Employees are likely affected by the loss of a colleague and the need to transition responsibilities.
• Customers and partners may be reassured by the reaffirmation of financial expectations and continued progress on regulatory approvals.

Next Steps

• The company will report fourth quarter and full year 2024 financial results on March 25, 2025.
• Management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30 PM ET on March 25, 2025.
• The company expects to file its Form 10-K in that timeframe.
• The company continues to await regulatory decisions on DrugSorb-ATR marketing applications from the U.S. FDA and Health Canada in 2025.

Key Dates